Skip to main content

by Dr. C.H. Weaver M.D. 7/2020

The FDA has granted an Orphan Drug Designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction (GEJ) cancer, according to a press release from developer Leap Therapeutics. (1)

About DKN-01

DKN-01 is a novel humanized monoclonal antibody that targets the DKK1 protein, which modulates Wnt/beta-catenin signaling. DKK1 is known to play a role in cancer cell signaling and mediating an immunosuppressive cancer microenvironment by boosting the activity of myeloid-derived suppressor cells and down regulating natural killer ligands on cancer cells which may prevent cancer cell growth.

The KEYNOTE-731 clinical trial is exploring the use of DKN-01 alone and in combination with paclitaxel chemotherapy or Keytruda (pembrolizumab) immunotherapy in patients with advanced esophagogastric cancers who have been previously treated with standard therapies

The combination of DKN-01 plus a PD-1 checkpoint inhibitor in patients with advanced or recurrent gastroesophageal adenocarcinoma who had no prior exposure to PD-1/PD-L1 checkpoint blockade has anti-cancer activity in patients with a high tumor DKK1 expression. (2,3) The objective response rate among the 10 evaluable patients with high DKK1 expression on cancer cells was 50% and the disease control rate in these patients was 80%. Patients with low DKK1 expression did not appear to derive benefit from treatment.

Scroll to Continue

Recommended Articles


Neulasta Treatment of Neutropenia Improves Treatment

Understand the role of Neulasta treatment of Neutropenia to prevent infection and improve chemotherapy treatment.

Ask The Experts About COVID-19 and Myeloproliferative Neoplasms (MF - PV - ET) Komrokji Verstovsek Promo

Ask The Experts About COVID-19 and Myeloproliferative Neoplasms (MF - PV - ET)

PV, ET and MF are effectively treated during the COVID-19 pandemic - ask the experts about how best to manage your MPN.

Sun Safety

Sun Safety During Cancer Treatment

Chemotherapy, radiation, and other cancer therapies may cause skin irritations, making you more vulnerable to UV damage.


  1. doi10.1158/0008-5472.CAN-08-4135
  2. Klempner SJ, Bendell JC, Villaflor VM, et al. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. J Clin Oncol. 2020;38(suppl 4):357.
  3. Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting